138 related articles for article (PubMed ID: 20615891)
1. TP53 Arg72Pro polymorphism and colorectal cancer risk: a systematic review and meta-analysis.
Dahabreh IJ; Linardou H; Bouzika P; Varvarigou V; Murray S
Cancer Epidemiol Biomarkers Prev; 2010 Jul; 19(7):1840-7. PubMed ID: 20615891
[TBL] [Abstract][Full Text] [Related]
2. Genotype misclassification in genetic association studies of the rs1042522 TP53 (Arg72Pro) polymorphism: a systematic review of studies of breast, lung, colorectal, ovarian, and endometrial cancer.
Dahabreh IJ; Schmid CH; Lau J; Varvarigou V; Murray S; Trikalinos TA
Am J Epidemiol; 2013 Jun; 177(12):1317-25. PubMed ID: 23729685
[TBL] [Abstract][Full Text] [Related]
3. The association between the TP53 Arg72Pro polymorphism and colorectal cancer: An updated meta-analysis based on 32 studies.
Tian X; Dai S; Sun J; Jiang S; Jiang Y
Oncotarget; 2017 Jan; 8(1):1156-1165. PubMed ID: 27901479
[TBL] [Abstract][Full Text] [Related]
4. Genetic polymorphisms of TP53 (rs1042522) and MDM2 (rs2279744) and colorectal cancer risk: An updated meta-analysis based on 59 case-control studies.
Elshazli RM; Toraih EA; Elgaml A; Kandil E; Fawzy MS
Gene; 2020 Apr; 734():144391. PubMed ID: 32001373
[TBL] [Abstract][Full Text] [Related]
5. Association between p53 Arg72Pro polymorphism and colorectal cancer risk in Asian population: a meta-analysis.
Zhang Y; Zhang D; Zhao L; Sun L; Dong Q; Cheng L; Cheng R
Curr Probl Cancer; 2018 Nov; 42(6):582-592. PubMed ID: 30316510
[TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphisms in TP53, nonsteroidal anti-inflammatory drugs and the risk of colorectal cancer: evidence for gene-environment interaction?
Tan XL; Nieters A; Hoffmeister M; Beckmann L; Brenner H; Chang-Claude J
Pharmacogenet Genomics; 2007 Aug; 17(8):639-45. PubMed ID: 17622940
[TBL] [Abstract][Full Text] [Related]
7. Quantitative assessment of the association between TP53 Arg72Pro polymorphism and bladder cancer risk.
Liu ZH; Bao ED
Mol Biol Rep; 2013 Mar; 40(3):2389-95. PubMed ID: 23184052
[TBL] [Abstract][Full Text] [Related]
8. Association between TP53 Arg72Pro polymorphism and leukemia risk: a meta-analysis of 14 case-control studies.
Tian X; Dai S; Sun J; Jiang S; Jiang Y
Sci Rep; 2016 Apr; 6():24097. PubMed ID: 27053289
[TBL] [Abstract][Full Text] [Related]
9. TP53 Arg72Pro polymorphism (rs1042522) and risk of endometriosis among Asian and Caucasian populations.
Li J; Chen Y; Mo Z; Li L
Eur J Obstet Gynecol Reprod Biol; 2015 Jun; 189():73-8. PubMed ID: 25889195
[TBL] [Abstract][Full Text] [Related]
10. TP53 Arg72Pro polymorphism and endometrial cancer risk: a meta-analysis.
Jiang DK; Yao L; Ren WH; Wang WZ; Peng B; Yu L
Med Oncol; 2011 Dec; 28(4):1129-35. PubMed ID: 20552298
[TBL] [Abstract][Full Text] [Related]
11. p.Arg72Pro polymorphism of P53 and breast cancer risk: a meta-analysis of case-control studies.
Diakite B; Kassogue Y; Dolo G; Wang J; Neuschler E; Kassogue O; Keita ML; Traore CB; Kamate B; Dembele E; Nadifi S; Murphy RL; Doumbia S; Hou L; Maiga M
BMC Med Genet; 2020 Oct; 21(1):206. PubMed ID: 33076844
[TBL] [Abstract][Full Text] [Related]
12. TP53 Arg72Pro polymorphism is associated with esophageal cancer risk: a meta-analysis.
Jiang DK; Yao L; Wang WZ; Peng B; Ren WH; Yang XM; Yu L
World J Gastroenterol; 2011 Mar; 17(9):1227-33. PubMed ID: 21448430
[TBL] [Abstract][Full Text] [Related]
13. Effect of TP53 rs1042522 on the susceptibility of patients to oral squamous cell carcinoma and oral leukoplakia: a meta-analysis.
Sun Z; Gao W; Cui JT
BMC Oral Health; 2018 Aug; 18(1):143. PubMed ID: 30126398
[TBL] [Abstract][Full Text] [Related]
14. Arg72Pro TP53 polymorphism and cancer susceptibility: a comprehensive meta-analysis of 302 case-control studies.
Francisco G; Menezes PR; Eluf-Neto J; Chammas R
Int J Cancer; 2011 Aug; 129(4):920-30. PubMed ID: 20886596
[TBL] [Abstract][Full Text] [Related]
15. TP 53 polymorphisms and melanoma: A meta-analysis.
He T; Wu J; Chen Y; Zhang J
J Cancer Res Ther; 2015; 11(2):409-14. PubMed ID: 26148609
[TBL] [Abstract][Full Text] [Related]
16. TP53 Codon 72 Polymorphism and the Risk of Colorectal Cancer in an Azerbaijani Population.
Yagublu V; Bayramov B; Yuce M; Aslanov H
Turk J Gastroenterol; 2022 Jun; 33(6):485-490. PubMed ID: 35786616
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of associations between ATM Asp1853Asn and TP53 Arg72Pro polymorphisms and adverse effects of cancer radiotherapy.
Su M; Yin ZH; Wu W; Li XL; Zhou BS
Asian Pac J Cancer Prev; 2014; 15(24):10675-81. PubMed ID: 25605158
[TBL] [Abstract][Full Text] [Related]
18. Association between TP53 Arg72Pro polymorphism and hepatocellular carcinoma risk: a meta-analysis.
Xu CT; Zheng F; Dai X; Du JD; Liu HR; Zhao L; Li WM
Asian Pac J Cancer Prev; 2012; 13(9):4305-9. PubMed ID: 23167333
[TBL] [Abstract][Full Text] [Related]
19. Association of TP53 rs1042522 with cervical cancer in the sub-Saharan African population: a meta-analysis.
Kamiza AB; Kamiza S; Singini MG; Mathew CG
Trop Med Int Health; 2020 Jun; 25(6):666-672. PubMed ID: 32233050
[TBL] [Abstract][Full Text] [Related]
20. GSTP1 Ile105Val polymorphism and colorectal cancer risk: an updated analysis.
Tan Z; Feng M; Luo Y; Sun C; Fan Z; Tan Y; Fu B; Lang J
Gene; 2013 Sep; 527(1):275-82. PubMed ID: 23811488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
